Cidara Therapeutics (NASDAQ:CDTX) Given “Overweight” Rating at Cantor Fitzgerald

Cidara Therapeutics (NASDAQ:CDTX)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and set a $120.00 target price on shares of Cidara Therapeutics in a report on Monday, April 8th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $93.33.

Cidara Therapeutics Price Performance

Shares of Cidara Therapeutics stock opened at $12.29 on Tuesday. The firm has a fifty day moving average price of $15.40 and a 200 day moving average price of $15.35. Cidara Therapeutics has a 1 year low of $10.00 and a 1 year high of $29.60. The stock has a market cap of $1.11 billion, a PE ratio of -51.21 and a beta of 0.98.

Hedge Funds Weigh In On Cidara Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CDTX. Pale Fire Capital SE acquired a new position in Cidara Therapeutics during the third quarter worth about $51,000. Flagship Harbor Advisors LLC acquired a new position in Cidara Therapeutics during the third quarter worth about $28,000. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in Cidara Therapeutics by 25.2% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 15,912 shares during the last quarter. 35.82% of the stock is currently owned by institutional investors and hedge funds.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.